Recent Press Releases

Neovacs Announces Top Line Phase IIb Clinical Trial Results of TNF-Kinoid in Rheumatoid Arthritis and Update on Clinical Programs

Phase IIb clinical trial of TNF-Kinoid in Rheumatoid Arthritis confirmed the good safety profile as well as antibody production, but failed to meet efficacy endpoints. Further evaluation is ongoing....

Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE™ Technology

SAN DIEGO, Dec. 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen Biotech, Inc....

POZEN's YOSPRALA™ Receives Complete Response Letter from The FDA

CHAPEL HILL, N.C.-- POZEN Inc. (POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that their investigational drug candidates YOSPRALA™...

Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics

FOSTER CITY, Calif., Dec 15, 2014 (BUSINESS WIRE) -- Gilead Sciences, Inc. GILD, -1.19% today announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and...

Galapagos regains full rights to GPR84 inhibitor GLPG1205

Program to enter first Phase 2 patient study in ulcerative colitis this month MECHELEN, Belgium, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today it has agreed with...

Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis

- DSMB determined that the planned futility boundary has been crossed; but saw no reason for patients to discontinue from study - - Conference Call Scheduled December 16, 2014 at 9:00 a.m. EST -...

BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates

Jerusalem, Israel – December 16, 2014 – BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR, a next-generation somatostatin analog, provides a new...

Sorrento Announces Strategic Investment By And Collaboration With Nantworks Founder Dr. Patrick Soon-Shiong For The Advancement Of Cancer Immunotherapies

SAN DIEGO, Dec. 15, 2014 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that it has entered...

Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 Agreement Reached With Both FDA and EMA on Pivotal Trial Design NOVATO,...

Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity

Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity BOSTON, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to...

BerGenBio Completes NOK90 Million Fundraising

BerGenBio Completes NOK90 Million Fundraising BERGEN, Norway, December 15, 2014 /PRNewswire/ -- BerGenBio AS, a biopharmaceutical company focused on developing innovative drugs for aggressive drug...

Exelixis' Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma

Exelixis, Inc. (EXEL) today announced its collaborator Genentech, a member of the Roche Group, has completed the filing of its New Drug Application (NDA) with the U.S. Food and Drug Administration...

David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer

BOSTON, Dec 15, 2014 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated today announced that David Altshuler, M.D., Ph.D., will join the company as Executive Vice President, Global Research and...

Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

SAN DIEGO & VANCOUVER, British Columbia--Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the...

Annexon Bioscience Closes $34M Series A-1 Funding for Novel Approach to Neurodegenerative and Autoimmune Diseases

Annexon Bioscience Closes $34M Series A-1 Funding for Novel Approach to Neurodegenerative and Autoimmune Diseases December 15, 2014 09:00 AM Eastern Standard Time REDWOOD CITY, Calif.--Annexon...

BioTime Appoints Angus C. Russell to Board of Directors

BioTime Appoints Angus C. Russell to Board of Directors

OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)

OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP) - hGH-CTP in global clinical development for the treatment of pediatric and adult growth hormone...